BioCentury
ARTICLE | Clinical News

Hepatitis C: Phase IIb data

June 6, 2005 7:00 AM UTC

In the Phase IIb (study 916) trial in patients with chronic HCV infection, HCV E1 vaccine missed the primary endpoint of percent of patients with at least a 1-point improvement in liver fibrosis vs. ...